Awakn Life Sciences Corp.: Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect
Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II Toronto, Ontario--(Newsfile Corp. - January 24, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:
Source: finanznachrichten.de